Two-year Outcomes of Remission Induction Therapy with Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis: A Case Series
Intern Med. 2025 Oct 23. doi: 10.2169/internalmedicine.5825-25. Online ahead of print. ABSTRACT Mepolizumab, which selectively suppresses IL-5, has been proven […]

